The loss of the identity of insulin-secreting beta cells in the islet of Langerhans, a process also called beta cell dedifferentiation, has been proposed to be a main reason for the development of diabetes. If and how dedifferentiated beta cells can be targeted by pharmacological intervention for beta cell regeneration is unknown. In a new study in mice, Helmholtz Zentrum München in collaboration with Novo Nordisk, demonstrated for the first time that a targeted combinatorial drug treatment is able to restore beta cell function, achieve beta cell redifferentiation and therefore potentially open new ways for diabetes remission.
Read More
Health Rss 